Physician profile
Michael L Fox
NPI 1558444711
$38,775.36
in general payments reported to CMS, 2019-2025
42 companies · $3,051 in 2025
The $3,051 reported for 2025 was more than what 94% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $3,646 · 2021: $1,916 · 2022: $1,716 · 2023: $726 · 2024: $1,174 · 2025: $3,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,654 · Travel and Lodging: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.83 |
| Travel and Lodging | $1,297.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $14,206.49 | 2019-2020 | |
| Alkermes, INC. | $10,230.24 | 2019-2025 | Vivitrol, Vivitrol |
| Orexo US, INC. | $3,708.47 | 2019-2025 | Zubsolv |
| Abbvie INC. | $2,067.94 | 2019-2025 | |
| Stryker Corporation | $1,359.02 | 2025 | Inspace, Iconix, Salvation |
| Teva Pharmaceuticals USA, INC. | $1,074.79 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Uswm, LLC | $799.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $798.80 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $538.13 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $480.89 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $431.94 | 2019-2025 | Ingrezza |
| Allergan, INC. | $317.94 | 2019-2020 | |
| Novo Nordisk INC | $301.29 | 2019-2025 | Ozempic, Rybelsus |
| Jazz Pharmaceuticals INC. | $289.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $274.19 | 2019-2025 | Trelegy Ellipta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.